Abstract
We have designed and evaluated a dual anticancer delivery system to provide combined gene therapy and chemotherapy. Double-walled microspheres consisting of a poly(d,l-lactic-co-glycolic acid) (PLGA) core surrounded by a poly(lactic acid) (PLA) shell were fabricated via the precision particle fabrication (PPF) technique. We make use of the advantages of double-walled microspheres to deliver chitosan-DNA nanoparticles containing the gene encoding the p53 tumor suppressor protein (chi-p53) and/or doxorubicin (Dox), loaded in the shell and core phases, respectively. Different molecular weights of PLA were used to form the shell layer for each formulation. The microspheres were monodisperse with a mean diameter of 65 to 75 μm and uniform shell thickness of 8 to 17 μm. Blank and Dox-loaded microspheres typically exhibited a smooth surface with relatively few small pores, while chi-microspheres containing p53 nanoparticles, with and without Dox, presented rough and porous surfaces. The encapsulation efficiency of Dox was significantly higher when it was encapsulated alone compared to co-encapsulation with chi-p53 nanoparticles. The encapsulation efficiency of chi-p53 nanoparticles, on the other hand, was not affected by the presence of Dox. As desired, chi-p53 nanoparticles were released first, followed by simultaneous release of chi-p53 nanoparticles and Dox at a near zero-order rate. Thus, we have demonstrated that the PPF method is capable of producing double-walled microspheres and encapsulating dual agents for combined modality treatment, such as gene therapy and chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 130-135 |
| Number of pages | 6 |
| Journal | Journal of Controlled Release |
| Volume | 163 |
| Issue number | 2 |
| DOIs | |
| State | Published - Oct 28 2012 |
Bibliographical note
Funding Information:The authors acknowledge the funding support from the National Institutes of Health (NIH, USA) and National Medical Research Council (NMRC, Singapore) under the grant numbers 1R01EB005181 and NMRC EDG11may084 , respectively. Qingxing Xu acknowledges the scholarship support from Agency for Science, Technology and Research (A*STAR, Singapore) for NUS-UIUC Joint Ph.D. Program.
Funding
The authors acknowledge the funding support from the National Institutes of Health (NIH, USA) and National Medical Research Council (NMRC, Singapore) under the grant numbers 1R01EB005181 and NMRC EDG11may084 , respectively. Qingxing Xu acknowledges the scholarship support from Agency for Science, Technology and Research (A*STAR, Singapore) for NUS-UIUC Joint Ph.D. Program.
| Funders | Funder number |
|---|---|
| NUS-UIUC | |
| National Institutes of Health (NIH) | |
| National Institute of Biomedical Imaging and Bioengineering | R01EB005181 |
| National Institute of Biomedical Imaging and Bioengineering | |
| Agency for Science Technology and Research | |
| National Medical Research Council Singapore | 1R01EB005181, NMRC EDG11may084 |
| National Medical Research Council Singapore |
Keywords
- Chitosan
- Double-walled microspheres
- Doxorubicin
- Gene therapy
- PLGA
- p53
ASJC Scopus subject areas
- Pharmaceutical Science